TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9. A total of 49 filers reported holding TEVA PHARMACEUTICAL FIN LLC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $10,013,000 | -8.5% | 9,964,000 | -10.7% | 0.17% | -27.7% |
| Q3 2020 | $10,942,000 | -27.2% | 11,160,000 | -27.4% | 0.24% | -28.7% |
| Q2 2020 | $15,034,000 | +26.5% | 15,366,000 | +20.3% | 0.33% | 0.0% |
| Q1 2020 | $11,883,000 | -4.1% | 12,771,000 | -1.8% | 0.33% | +43.3% |
| Q4 2019 | $12,389,000 | +290.9% | 13,001,000 | +273.6% | 0.23% | +275.8% |
| Q3 2019 | $3,169,000 | -54.1% | 3,480,000 | -53.7% | 0.06% | -51.9% |
| Q2 2019 | $6,907,000 | -46.3% | 7,511,000 | -45.9% | 0.13% | -47.1% |
| Q1 2019 | $12,863,000 | -83.7% | 13,878,000 | -84.0% | 0.24% | -66.0% |
| Q4 2018 | $78,756,000 | +399.8% | 86,786,000 | +418.0% | 0.72% | +238.7% |
| Q3 2018 | $15,756,000 | -3.8% | 16,755,000 | -4.7% | 0.21% | -7.4% |
| Q2 2018 | $16,379,000 | +17.5% | 17,577,000 | +11.1% | 0.23% | +3.6% |
| Q1 2018 | $13,944,000 | +10.5% | 15,820,000 | +10.6% | 0.22% | +11.6% |
| Q4 2017 | $12,624,000 | – | 14,305,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Radcliffe Capital Management, L.P. | 70,783,000 | $69,363,000 | 6.27% |
| INCOME RESEARCH & MANAGEMENT | 14,978,000 | $14,536,000 | 5.17% |
| PIPER SANDLER & CO. | 5,000,000 | $4,852,000 | 3.63% |
| Western Asset Management Company, LLC | 42,946,000 | $42,102,000 | 3.46% |
| PenderFund Capital Management Ltd. | 4,000,000 | $5,225,000 | 1.45% |
| Bracebridge Capital, LLC | 5,500,000 | $5,335,000 | 0.85% |
| WESTWOOD HOLDINGS GROUP INC | 43,185,000 | $42,490,000 | 0.54% |
| CORBYN INVESTMENT MANAGEMENT INC/MD | 1,025,000 | $995,000 | 0.52% |
| LMR Partners LLP | 22,235,000 | $21,742,000 | 0.45% |
| JUPITER ASSET MANAGEMENT LTD | 35,000,000 | $34,357,000 | 0.36% |